Kaiser Health News: Mylan’s Generic EpiPen — A Price Break Or Marketing Maneuver?
Kaiser Health News staff writer Julie Appleby reports: Following weeks of criticism over dramatic price increases on its EpiPen, Mylan said Monday it will offer a generic version of the life-saving allergy treatment. The generic, which the company says will be identical to the brand product, will sell for $300 for a two-pack, which is half the cost of Mylan’s brand name EpiPens. The news did little to dim the ongoing outcry over the price, for which there are no other competitors on the market. Some called it a marketing ploy. ... KHN offers answers to some key questions related to Mylan’s generic and breaks down what this development could mean for consumers and the marketplace. (Appleby, 9/1)